First Time Loading...

ReShape Lifesciences Inc
NASDAQ:RSLS

Watchlist Manager
ReShape Lifesciences Inc Logo
ReShape Lifesciences Inc
NASDAQ:RSLS
Watchlist
Price: 0.1844 USD 1.77% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

RSLS doesn't have a meaningful market cap.
RSLS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

ReShape Lifesciences, Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. [ Read More ]

The intrinsic value of one RSLS stock under the Base Case scenario is 1.3665 USD. Compared to the current market price of 0.1844 USD, ReShape Lifesciences Inc is Undervalued by 87%.

Key Points:
RSLS Intrinsic Value
Base Case
1.3665 USD
Undervaluation 87%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ReShape Lifesciences Inc

Backtest RSLS Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling RSLS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of ReShape Lifesciences Inc's business.

What risks and challenges
does ReShape Lifesciences Inc face in the near future?

Summarize the latest earnings report
of ReShape Lifesciences Inc.

Provide P/E
for ReShape Lifesciences Inc and its competitors.

Financials

Balance Sheet Decomposition
ReShape Lifesciences Inc

Current Assets 7.4m
Cash & Short-Term Investments 1.4m
Receivables 2.2m
Other Current Assets 3.8m
Non-Current Assets 400k
PP&E 300k
Other Non-Current Assets 100k
Current Liabilities 4.5m
Accounts Payable 1.5m
Accrued Liabilities 2m
Other Current Liabilities 1m
Non-Current Liabilities 200k
Other Non-Current Liabilities 200k
Efficiency

Earnings Waterfall
ReShape Lifesciences Inc

Revenue
9.8m USD
Cost of Revenue
-4.5m USD
Gross Profit
5.3m USD
Operating Expenses
-22.8m USD
Operating Income
-17.5m USD
Other Expenses
-8.8m USD
Net Income
-26.3m USD

Free Cash Flow Analysis
ReShape Lifesciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

RSLS Profitability Score
Profitability Due Diligence

ReShape Lifesciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
ROIC is Increasing
Positive Revenue Growth Forecast
28/100
Profitability
Score

ReShape Lifesciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

RSLS Solvency Score
Solvency Due Diligence

ReShape Lifesciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
50/100
Solvency
Score

ReShape Lifesciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RSLS Price Targets Summary
ReShape Lifesciences Inc

Wall Street analysts forecast RSLS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RSLS is 1.02 USD with a low forecast of 1.01 USD and a high forecast of 1.05 USD.

Lowest
Price Target
1.01 USD
448% Upside
Average
Price Target
1.02 USD
453% Upside
Highest
Price Target
1.05 USD
469% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

RSLS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

RSLS Price
ReShape Lifesciences Inc

1M 1M
+10%
6M 6M
-46%
1Y 1Y
-94%
3Y 3Y
-100%
5Y 5Y
-100%
10Y 10Y
-100%
Annual Price Range
0.1844
52w Low
0.1515
52w High
3.13
Price Metrics
Average Annual Return -62.55%
Standard Deviation of Annual Returns 29.57%
Max Drawdown -100%
Shares Statistics
Market Capitalization 4.3m USD
Shares Outstanding 23 460 000
Percentage of Shares Shorted 3.23%

RSLS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

ReShape Lifesciences Inc Logo
ReShape Lifesciences Inc

Country

United States of America

Industry

Health Care

Market Cap

4.3m USD

Dividend Yield

0%

Description

ReShape Lifesciences, Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. The company is headquartered in San Clemente, California and currently employs 47 full-time employees. The company went IPO on 2016-10-06. The firm is focused on offering an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band and associated program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest System is an investigational minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. The ReShapeCare Virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. The firm's Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kilograms/ square meter.

Contact

CALIFORNIA
San Clemente
1001 Calle Amanecer
+19494296680.0
https://www.reshapelifesciences.com/obalon/

IPO

2016-10-06

Employees

47

Officers

Executive Chair
Mr. Dan W. Gladney
CEO, President & Director
Mr. Paul F. Hickey
Chief Financial Officer
Mr. Thomas Stankovich
Co-Founder and Special Advisor to the CEO
Dr. Mark B. Knudson Ph.D.
Co-Founder
Dr. Katherine S. Tweden Ph.D.
Vice President of Operations and R&D
Mr. Al Diaz
Show More
VP of Regulatory Clinical Quality & Compliance Officer
Dr. Dov Gal D.V.M., M.B.A.
Director of Communications
Jody B. Dahlman
Senior Vice President of Global Commercial Operations
Mr. Naqeeb A. Ansari
Show Less

See Also

Discover More
What is the Intrinsic Value of one RSLS stock?

The intrinsic value of one RSLS stock under the Base Case scenario is 1.3665 USD.

Is RSLS stock undervalued or overvalued?

Compared to the current market price of 0.1844 USD, ReShape Lifesciences Inc is Undervalued by 87%.